SCHEMBL21144966

SCHEMBL21144966

N#Cc1ccc(CC(N)CC(=O)NCCCO)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 4/20 0.47
MKNK1 Q9BUB5 1/20 0.39
MKNK2 Q9HBH9 1/20 0.39
MMP2 P08253 1/20 0.38
MGLL Q99685 2/20 0.38
AOC3 Q16853 1/20 0.38
FAP Q12884 2/20 0.37
DPP8 Q6V1X1 2/20 0.37
DPP9 Q86TI2 2/20 0.37
DPP7 Q9UHL4 2/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
CCR3 P51677 1/20 0.37
SAE1 Q9UBE0 1/20 0.37
UBA2 Q9UBT2 1/20 0.37
CTSC P53634 1/20 0.37
KCNH2 Q12809 1/20 0.37
ABCB1 P08183 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21144963 1.00 DPP4 (0.47) DPP4MKNK1MKNK2MMP2MGLL
SCHEMBL21144806 0.92 DPP4 (0.49) DPP4MKNK1MKNK2MMP2FAP
SCHEMBL21144808 0.92 DPP4 (0.49) DPP4MKNK1MKNK2MMP2FAP
SCHEMBL21144704 0.81 MME (0.42) MKNK1MKNK2MGLLPOLBMAPT
SCHEMBL21144702 0.81 MME (0.42) MKNK1MKNK2MGLLPOLBMAPT
SCHEMBL18920628 0.80 DPP4 (0.52) DPP4MMP2FAPDPP8DPP9
SCHEMBL21628944 0.80 DPP4 (0.52) DPP4MMP2FAPDPP8DPP9
Hydrochloric Acid SCHEMBL21144924 0.79 DPP4 (0.51) DPP4MMP2FAPDPP8DPP9
Hydrochloric Acid SCHEMBL21144921 0.79 DPP4 (0.51) DPP4MMP2FAPDPP8DPP9
SCHEMBL21169834 0.77 DPP4 (0.50) DPP4FAPDPP8DPP9DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654818-B2 Furane derivatives as inhibitors of ATAD2 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-05-19 US disclosed
US-10654818-B2 Furane derivatives as inhibitors of ATAD2 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-05-19 US disclosed
EP-3383865-B1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 Bayer Pharma AG (DE) 2020-01-29 EP disclosed
EP-3383865-B1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 Bayer Pharma AG (DE) 2020-01-29 EP disclosed
US-20190218196-A1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-07-18 US disclosed
US-20190218196-A1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218196-A1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 ATAD2, ATAD2B, TAF1L DPP4 3896/4885MKNK1 2893/4885MKNK2 2082/4885
US-10654818-B2 Furane derivatives as inhibitors of ATAD2 ATAD2, ATAD2B, TAF1L DPP4 3896/4885MKNK1 2893/4885MKNK2 2082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.